Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Restaxil UMP B-Komplex
- Development stage
- Unknown
- Lead developer
- PharmaSGP
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Restaxil UMP B-Komplex is a dietary supplement developed by PharmaSGP. It is formulated to support the regeneration of peripheral nerves and maintain healthy nervous system function. The product combines uridine monophosphate (UMP) with a complete vitamin B complex (including vitamins B1, B2, B3, B5, B6, B7, B9, and B12) and calcium. These ingredients work synergistically to support normal neurotransmission, protect nerve cells from oxidative stress, and aid in the synthesis and metabolism of neurotransmitters.
- Brand names
- Restaxil UMP B-Komplex
- Other names
- Restaxil UMP B-Complex
02
Targets
P2RY2 (P2Y Purinoceptor 2)
Beyond the preview
Go deeper on Restaxil UMP B-Komplex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Restaxil UMP B-Komplex.